Close

Tiziana Life Sciences (TLSA) Announces Timetable of Demerger of Accustem

Go back to Tiziana Life Sciences (TLSA) Announces Timetable of Demerger of Accustem

Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

October 27, 2020 12:00 PM EDT

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Companys American Depositary Receipts (ADRs).

The demerger of Accustem is the spinoff of Tizianas StemPrintER, a novel biology-based genomic predictor of distant recurrence... More